5 Reasons Why Biotech ETFs Are Soaring
Zacks Investment Research | Jun 21, 2017 11:17PM ET
The biotech sector is going through the roof right now with SPDR S&P Biotech (MX:XBI) ETF three-day streak since November.”
A host of factors are powering the rally and we highlight some below.
Fears Over Price Gouging Ebbing
The pharma and biotech industry has been hit hard in recent times on the price gouging issue. The issue was first raised by Hillary Clinton in September 2015 and since thenthe space has been battered by increasing political and media focus on high prices for some drugs. Even President Trump occasionally bothered the sector on this issue.
However, the stringent approach is easing, allowing investors to enter the space all over again. As per Trump Tweet on Drug Pricing Hits Biotech and Pharma ETFs ).
AHCA to Benefit
President Donald Trump has basically pledged to reduce FDA regulations, which may prove to be a boon to the space. The republican proposed American Health Care Act (AHCA) would benefit companies by removing billions of dollars in taxes and fees on pharmaceutical and medical-device manufacturers.
As per an article published on Bloomberg, “extending the patent life of drugs in foreign markets; promoting U.S. drug market competition; value-based agreements; and issuing U.S. Treasury bonds to drug manufacturers to help pay for expensive treatments” will now be the focus.
Next week, the Senate is likely to vote on the health-care reform bill. If AHCA clears this hurdle, it might be a blessing for biotech, or rather the broader health care space.
Positive Clinical Trials
Successful clinical trials for new drugs has been another tailwind for the space. Clovis Oncology (NASDAQ:CLVS) shares gained 46.5% on June 19 following the company’s positive cancer drug data. The company said clinical trial data on its ovarian cancer drug treatment indicated that it may substantially help more patients than expected. The news acted as a catalyst for the entire space (read: 4 Stocks & ETFs to Buy on Clovis' Positive Drug Data ).
Increasing M&A Activity
Merger and acquisitions have been great for biotech companies in the last few years to reduce competition for the same kind of offerings and attain synergies. And the activity is expected to continue in the coming days as well.
For example, Clovis’ drug news led rival Tesaro's shares to decline, as per Merger Arbitrage 101: Investing in Acquisitions with an ETF? ).
Compelling Valuation
Biotech stocks were the SPY is up 9.7%. Biotech stocks now “trade at an average 16.4 times projected 12-month earnings, compared with 17.7 for the benchmark, the narrowest discount in more than 10 months,” as per Bloomberg.
Get The News You Want
ETFs to Tap at Highs
Below we highlight a few biotech ETFs that are on a 52-week high and may log more return’s ahead.
Direxion S&P Biotech Bull 3X LABU
Ultrapro Nasdaq Biotechnology Proshares UBIO
ProShares Ultra Nasdaq Biotechnology BIB
iShare Nasdaq Biotech ETF IBB
Bioshares Biotech Clinical Trial (HM:BBC)
VanEck Vectors Biotech ETF (LON:BBH)
Bioshares Biotech Products (BS:BBP)
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.